SecBot SecBot
PRESS-RELEASE ·Filed Mar 27, 2026

TIL

Instil Bio
MIXED
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Traders should monitor for potential M&A or in-licensing announcements, which could catalyze upside. However, the lack of an internal pipeline and declining cash raise execution risk despite improved cost discipline.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.79
T+0 close · Mar 27, 2026 · via day close
Latest settled
−1.41%
T+60 · $7.68
Vs SPY
−17.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $7.79entry
  2. T+1 · 8mo ago +2.31%α +2.67% · $7.97
  3. T+5 · 8mo ago +8.60%α +4.74% · $8.46
  4. T+20 · 7mo ago +4.36%α −8.38% · $8.13
  5. T+60 · 5mo ago −1.41%α −17.48% · $7.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Instil Bio reported its Q4 and full-year 2025 financial results, showing a reduced net loss compared to the prior year despite declining cash reserves. The company discontinued development of AXN-2510 and is now focusing on external growth through acquisitions and in-licensing, with a cash runway expected to fund operations beyond 2027.

Key Financial Metrics

Adj. EPS
$-6.91
GAAP: $-10.70

Key Facts

  • Net loss for full year 2025 was $71.37 million ($10.70 per share), improved from $74.14 million ($11.39 per share) in 2024.
  • Cash, cash equivalents, restricted cash, and marketable securities declined to $76.3 million as of December 31, 2025, from $115.1 million a year earlier.
  • The company discontinued AXN-2510 development and terminated its collaboration with ImmuneOnco Biopharmaceuticals.
  • Instil is now pursuing acquisitions and in-licensing opportunities to build a new pipeline.
  • Non-GAAP net loss per share improved to $6.91 in 2025 from $7.59 in 2024.

Financial Impact

Cash position decreased by $38.8 million year-over-year; full-year net loss decreased by $2.77 million. Non-GAAP net loss improved by $3.33 million.

cashnet_lossepsnon_gaap_eps

Risk Factors

  • No current internal pipeline following discontinuation of AXN-2510.
  • Execution risk in identifying and closing external innovation deals.
  • Dilution risk if future transactions are funded through equity.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263677

Track record

8 reports on TIL

Performance horizon
Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry $6.22 Now $5.75 −7.56% settles Dec 15
  2. Aug 13, 202613w ago Press Release Neutral 4/10 No price data
  3. Aug 13, 202613w ago 8-K Neutral 4/10 Entry $7.38 to $7.45 Now $5.75 −22.09% ▲ +0.95% +2.94% vs SPY
  4. May 15, 202626w ago 8-K Neutral 4/10 No price data
  5. May 15, 202626w ago Press Release Neutral 4/10 Entry $8.07 to $7.92 Now $5.75 −28.75% ▼ −1.86% −3.98% vs SPY
  6. Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $8.13 to $8.12 Now $5.75 −29.27% ▼ −0.12% −5.08% vs SPY
  7. Apr 3, 202632w ago 8-K Neutral 4/10 Entry $8.46 to $7.84 Now $5.75 −32.03% ▼ −7.33% −16.31% vs SPY
  8. Mar 27, 202633w ago Press Release Mixed 5/10 Viewing Entry $7.79 to $8.13 Now $5.75 −26.19% ▲ +4.36% −8.38% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 27, 2026